Focused On-demand Library for Glycolipid transfer protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9NZD2

UPID:

GLTP_HUMAN

Alternative names:

Alternative UPACC:

Q9NZD2; Q53Z13; Q96J68

Background:

The Glycolipid transfer protein, identified by the accession number Q9NZD2, plays a crucial role in cellular processes by accelerating the intermembrane transfer of various glycolipids. It specifically catalyzes the transfer of glycosphingolipids between membranes, a process essential for maintaining cellular membrane integrity and function, but does not interact with phospholipids. This specificity towards glycosphingolipids highlights its unique function in cellular lipid metabolism.

Therapeutic significance:

Understanding the role of Glycolipid transfer protein could open doors to potential therapeutic strategies. Its involvement in the intracellular translocation of glucosylceramides suggests a pivotal role in cellular lipid homeostasis, which, if modulated, could offer new avenues for treating diseases related to lipid metabolism disorders.